ArticleThoracic cancer2024

Immune-inflammatory markers and clinical characteristics as predictors of the depth of response and prognosis of patients with PD-L1 ≥50% metastatic non-small cell lung cancer receiving first-line immunotherapy.

Xixi Zheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.